Blog

Exhibition Invitation | IGC2025: The 10th International Conference on Research, Development, and Industrialization of Cells and Derivatives

Release Date:

2025-10-20 15:39

IGC 2025: The 10th International Conference on Cell and Derivative Research, Development, and Industrialization Will be October 30–31 In Langham Place, Guangzhou Grandly inaugurated. Leveraging the Greater Bay Area’s policy advantages, this conference features a main venue and four specialized sessions, bringing together Huaxi Lecheng, Xiangxue, Baiji, Dabo, China Resources, Guanhao, Keyi, North Science Sinovac, Laien, Tiankeya, Qianhui, Aierpu, Xidi, Ruizhen, Sipu, Ai Yi, Aixiuma Wait 60+ Experts from top research institutions, leaders of leading enterprises, and partners from investment firms will jointly explore In vivo immune cell therapy, MSC/iPSC stem cell therapy, exosome therapy, and anti-aging medical aesthetics and cutting-edge tracks.

 

 

 

Shanghai Hycells Biotechnology Co., Ltd. Will make an appearance Booth C11

We cordially invite industry colleagues to visit our booth for交流.

Jointly explore the latest scientific research findings to boost the thriving development of the cell industry!

 

Hycells Biology Company Introduction 

 

Shanghai Hycells Biotechnology Co., Ltd. Founded in 2021, the company has spent many years cultivating expertise in cell and gene therapy as well as large-molecule drug development, positioning itself as an innovative biotechnology firm that offers end-to-end integrated solutions spanning R&D, manufacturing, sales, and service for primary-cell–based products. To date, Hycells has established nearly 1,000 square meters of state-of-the-art R&D laboratories and has officially obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. The company has also been recognized as a “Shanghai High-Tech Enterprise” and a “Shanghai Specialized, Sophisticated, Distinctive, and Innovative SME.” Hycells is committed to becoming a world-leading one-stop provider of primary cells, associated reagents, and related services. Leveraging the platform advantages of its existing portfolio of immune-cell–related products and services, the company has built a robust and diversified donor pool comprising healthy donors from both China and abroad, and has developed a comprehensive donor management and project management system. This enables Hycells to offer clients end-to-end compliance support, including regulatory interpretation, policy analysis, domestic-investor designation, and international collaboration approval, ensuring full regulatory adherence throughout the approval process. Guided by core values that place talent at the foundation, quality first, and innovation at the heart of everything it does, Hycells uses technological innovation as its starting point to set new industry standards for domestic innovation and product substitution, thereby providing a solid foundation for the advancement and global leadership of China’s innovative pharmaceutical sector.

 

 

Introduction to Hycells Biological Products and Technologies 

- Sample Services -

Peripheral Blood

Mobilized Blood

Cord Blood

Primary cells of animal origin

Disease samples

 

- Cultured products (HiXpan

Previous page

Exhibition Invitation | The Inaugural Intelligent Technologies Forum for Drug Discovery and the WeMol User Conference

Little “Sheng” Has a Reason Learning Hall | TDCC Experimental Skills Intensive Training Course

Next page

Related News

(II) Security Assurance Section | Safety First, Defense Prioritized

Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.

(1) Compliance and Traceability Section | Establishing a Foundation of Compliance, Ensuring Source Tracing

This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.

Compliance as the Foundation, Safety as the Core | The Steadfast Commitment and Confidence Behind Heyou Sheng’s Serum Substitute

In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.

A novel mechanism by which iron overload in the tumor microenvironment triggers ferroptosis in CD8⁺ T cells | Guangzhou National Laboratory publishes in Nature Communications, revealing a key pathway of immune evasion (IF: 18.2)

Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.

Hycells Recruitment | Never Stop Exploring, Never Stop Innovating

The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.

3.0 High-Efficiency Version of HiXpan® NK Serum-Free Culture Kit | Chapter 4: Comprehensive Overview of Customer-Specific Culture Data Across Multiple Scenarios

The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.